» Articles » PMID: 35651298

Contemporaneous Symptom Networks of Multidimensional Symptom Experiences in Cancer Survivors: A Network Analysis

Overview
Journal Cancer Med
Specialty Oncology
Date 2022 Jun 2
PMID 35651298
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Symptom networks can provide empirical evidence for the development of personalized and precise symptom management strategies. However, few studies have explored the symptom networks of multidimensional symptom experiences in cancer survivors. The objectives of this study were to generate symptom networks of multidimensional symptom experiences in cancer survivors and explore the centrality indices and density in these symptom networks METHODS: Data from 1065 cancer survivors were obtained from the Shanghai CANcer Survivor (SCANS) Report. The MD Anderson Symptom Inventory was used to assess the prevalence and severity of 13 cancer-related symptoms. We constructed contemporaneous networks with all 13 symptoms after controlling for covariates.

Results: Distress (r  = 9.18, r  = 0.06), sadness (r  = 9.05, r  = 0.06), and lack of appetite (r  = 9.04, r  = 0.06) had the largest values for strength and closeness. The density of the "less than 5 years" network was significantly different from that of the "5-10 years" and "over 10 years" networks (p < 0.001). We found that while fatigue was the most severe symptom in cancer survivorship, the centrality of fatigue was lower than that of the majority of other symptoms.

Conclusion: Our study demonstrates the need for the assessment of centrality indices and network density as an essential component of cancer care, especially for survivors with <5 years of survivorship. Future studies are warranted to develop dynamic symptom networks and trajectories of centrality indices in longitudinal data to explore causality among symptoms and markers of interventions.

Citing Articles

Symptoms associated with concurrent chemoradiotherapy in patients with cervical cancer: Application of latent profile analysis and network analysis.

Lu X, Zheng L, Jin X, Wang Y, Wu S, Lv Y Asia Pac J Oncol Nurs. 2025; 12:100649.

PMID: 39896759 PMC: 11786907. DOI: 10.1016/j.apjon.2024.100649.


Symptom clusters and networks analysis in acute-phase stroke patients: a cross-sectional study.

Zhou S, Zhang Y, He H, Wang X, Li M, Zhang N Sci Rep. 2025; 15(1):2539.

PMID: 39833271 PMC: 11747254. DOI: 10.1038/s41598-024-84642-3.


Exploring early postoperative core symptoms in Chinese patients with primary liver cancer: a cross-sectional and longitudinal network analysis.

Zhang H, Li S, Yuan M, Liu J, Fan H, Li S Support Care Cancer. 2025; 33(2):104.

PMID: 39820759 DOI: 10.1007/s00520-024-09141-7.


Identifying core symptom clusters based on symptom distress levels in patients with maintenance hemodialysis: a cross-sectional network analysis.

Chang Y, Wang K, Liu M, Zhang Z, Ma H, Gao X Ren Fail. 2025; 47(1):2449203.

PMID: 39806785 PMC: 11734391. DOI: 10.1080/0886022X.2024.2449203.


Symptom clusters and network analysis in patients with gynecologic cancer undergoing chemotherapy: A cross-sectional study.

Zhang J, Wang S, Wang Y, Zhuang J, Hang L, Wu Y Asia Pac J Oncol Nurs. 2024; 11(12):100612.

PMID: 39641007 PMC: 11617375. DOI: 10.1016/j.apjon.2024.100612.


References
1.
Zhu Z, Xing W, Hu Y, Wu B, So W . Paradigm shift: Moving from symptom clusters to symptom networks. Asia Pac J Oncol Nurs. 2022; 9(1):5-6. PMC: 9072174. DOI: 10.1016/j.apjon.2021.12.001. View

2.
Rha S, Park M, Lee J . Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy. Support Care Cancer. 2018; 27(5):1687-1695. DOI: 10.1007/s00520-018-4413-9. View

3.
Zhu Z, Xing W, Zhang X, Hu Y, So W . Cancer survivors' experiences with financial toxicity: A systematic review and meta-synthesis of qualitative studies. Psychooncology. 2020; 29(6):945-959. DOI: 10.1002/pon.5361. View

4.
Portenoy R, Thaler H, Kornblith A, Lepore J, Kiyasu E, Sobel K . The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A(9):1326-36. DOI: 10.1016/0959-8049(94)90182-1. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View